{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:31:00Z","timestamp":1794274260564,"version":"4.9.0"},"reference-count":211,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.gendis.2026.102157","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:32:23Z","timestamp":1774110743000},"page":"102157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mitochondrial dynamics: A promising tool for personalized TNBC management"],"prefix":"10.1016","volume":"13","author":[{"given":"Harshit","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena B.","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8153-9598","authenticated-orcid":false,"given":"Manish Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"10.1016\/j.gendis.2026.102157_bib2","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.3390\/cancers13215350","article-title":"Molecular classification of breast cancer utilizing long non-coding RNA (lncRNA) transcriptomes identifies novel diagnostic lncRNA panel for triple-negative breast cancer","volume":"13","author":"Shaath","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib4","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41598-022-05502-6","article-title":"Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer","volume":"12","author":"Silvestri","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","article-title":"Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets","volume":"33","author":"Gong","year":"2021","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib6","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1038\/s41467-022-35059-x","article-title":"EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis","volume":"13","author":"Verma","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","article-title":"Overview of recent advances in metastatic triple negative breast cancer","volume":"12","author":"O\u2019Reilly","year":"2021","journal-title":"World J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102157_bib8","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190288","article-title":"Risk factors for distant metastasis of patients with primary triple-negative breast cancer","volume":"39","author":"Yao","year":"2019","journal-title":"Biosci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12885-018-4371-0","article-title":"Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer","volume":"18","author":"Jin","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/path.4280","article-title":"Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes","volume":"232","author":"Lehmann","year":"2014","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-016-0690-8","article-title":"Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer","volume":"18","author":"Liu","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.gendis.2026.102157_bib12","article-title":"Targeted therapeutic strategies for triple-negative breast cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/13510002.2022.2046423","article-title":"Role of mitochondrial reactive oxygen species in homeostasis regulation","volume":"27","author":"Zhang","year":"2022","journal-title":"Redox Rep"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/cells11050771","article-title":"Role of mitochondrial stress response in cancer progression","volume":"11","author":"Lee","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.gendis.2026.102157_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fonc.2020.00428","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"10","author":"Sun","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188518","article-title":"Mitochondrial dynamics, a new therapeutic target for triple negative breast cancer","volume":"1875","author":"Weiner-Gorzel","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.gendis.2026.102157_bib17","article-title":"New therapeutic directions in type II diabetes and its complications: mitochondrial dynamics","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102157_bib18","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100067R","article-title":"Mitochondrial fusion and fission: the fine-tune balance for cellular homeostasis","volume":"35","author":"Adebayo","year":"2021","journal-title":"FASEB J"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib19","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/onc.2015.227","article-title":"Disruption of cytochrome c oxidase function induces the Warburg effect and metabolic reprogramming","volume":"35","author":"Srinivasan","year":"2016","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"34","key":"10.1016\/j.gendis.2026.102157_bib21","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1038\/s41388-022-02408-5","article-title":"Glutamine addiction promotes glucose oxidation in triple-negative breast cancer","volume":"41","author":"Quek","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2026.102157_bib22","article-title":"The mechanism of Warburg effect-induced chemoresistance in cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12967-023-04498-5","article-title":"Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer","volume":"21","author":"Rocca","year":"2023","journal-title":"J Transl Med"},{"issue":"7844","key":"10.1016\/j.gendis.2026.102157_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41586-021-03214-x","article-title":"Function and regulation of the divisome for mitochondrial fission","volume":"590","author":"Kraus","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2026.102157_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.111008","article-title":"NOX4 alleviates breast cancer cell aggressiveness by co-ordinating mitochondrial turnover through PGC1\u03b1\/Drp1 axis","volume":"115","author":"Bhadane","year":"2024","journal-title":"Cell Signal"},{"issue":"40","key":"10.1016\/j.gendis.2026.102157_bib27","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/onc.2012.494","article-title":"Mitochondrial dynamics regulates migration and invasion of breast cancer cells","volume":"32","author":"Zhao","year":"2013","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.gendis.2026.102157_bib28","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1158\/0008-5472.CAN-19-1982","article-title":"MFF regulation of mitochondrial cell death is a therapeutic target in cancer","volume":"79","author":"Seo","year":"2019","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.gendis.2026.102157_bib29","first-page":"2422","article-title":"Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma","volume":"110","author":"Cantafio","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.gendis.2026.102157_bib30","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3389\/fonc.2020.01776","article-title":"Mitochondrial fission factor (MFF) inhibits mitochondrial metabolism and reduces breast cancer stem cell (CSC) activity","volume":"10","author":"S\u00e1nchez-Alvarez","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib31","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0229","article-title":"Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer","volume":"30","author":"Punter","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"13","key":"10.1016\/j.gendis.2026.102157_bib32","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1158\/1078-0432.CCR-15-2456","article-title":"Mitochondrial reprogramming regulates breast cancer progression","volume":"22","author":"Kannan","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib33","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.18632\/oncotarget.2795","article-title":"Mitochondrial translocation and interaction of cofilin and Drp1 are required for erucin-induced mitochondrial fission and apoptosis","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib34","first-page":"16","article-title":"Non-coding RNA-dependent regulation of mitochondrial dynamics in cancer pathophysiology","volume":"9","author":"Gallo Cantafio","year":"2023","journal-title":"Noncoding RNA"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12967-025-06077-2","article-title":"A review of the pathogenesis of mitochondria in breast cancer and progress of targeting mitochondria for breast cancer treatment","volume":"23","author":"Huang","year":"2025","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.gendis.2026.102157_bib36","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/cancers17071082","article-title":"Exploring the genetic orchestra of cancer: the interplay between oncogenes and tumor-suppressor genes","volume":"17","author":"Singh","year":"2025","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.gendis.2026.102157_bib37","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/biom15070970","article-title":"Targeting mitochondrial quality control for the treatment of triple-negative breast cancer: from molecular mechanisms to precision therapy","volume":"15","author":"Pei","year":"2025","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib38","first-page":"39","article-title":"Mitochondrial dynamics in breast cancer metastasis: from metabolic drivers to therapeutic targets","volume":"3","author":"Ruidas","year":"2025","journal-title":"Oncol Adv"},{"issue":"3191","key":"10.1016\/j.gendis.2026.102157_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2019.0210","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Cancer Biol Med"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12094-019-02187-8","article-title":"Emerging roles of aerobic glycolysis in breast cancer","volume":"22","author":"Wu","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2026.102157_bib42","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/0008-5472.CAN-17-2906","article-title":"Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the \u03b1-ketoglutarate signaling pathway","volume":"78","author":"Tseng","year":"2018","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad032","article-title":"PKM2 dictates the poised chromatin state of PFKFB3 promoter to enhance breast cancer progression","volume":"5","author":"Pandkar","year":"2023","journal-title":"NAR Cancer"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib44","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1007\/s11033-021-06414-w","article-title":"Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis","volume":"48","author":"Dev Arundhathi","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.gendis.2026.102157_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3119375","article-title":"Tumor microenvironment: lactic acid promotes tumor development","volume":"2022","author":"Gao","year":"2022","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib46","first-page":"119","article-title":"Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg effect","volume":"38","author":"San-Mill\u00e1n","year":"2017","journal-title":"Carcinogenesis"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib47","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1073\/pnas.1816391116","article-title":"Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways","volume":"116","author":"Jia","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gendis.2026.102157_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","article-title":"Glutaminolysis: a hallmark of cancer metabolism","volume":"19","author":"Yang","year":"2017","journal-title":"Annu Rev Biomed Eng"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib49","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.3390\/cimb46050282","article-title":"Oxidative stress in breast cancer: a biochemical map of reactive oxygen species production","volume":"46","author":"Bel\u2019skaya","year":"2024","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41598-017-18762-4","article-title":"Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.gendis.2026.102157_bib51","article-title":"The glutaminase-1 inhibitor 968 enhances dihydroartemisinin-mediated antitumor efficacy in hepatocellular carcinoma cells","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.gendis.2026.102157_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib53","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.celrep.2016.02.004","article-title":"Fatty acid oxidation-driven src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer","volume":"14","author":"Park","year":"2016","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nm.4055","article-title":"Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer","volume":"22","author":"Camarda","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib55","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cmet.2017.11.001","article-title":"JAK\/STAT3-regulated fatty acid \u03b2-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance","volume":"27","author":"Wang","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib56","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI71180","article-title":"MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis","volume":"124","author":"Terunuma","year":"2014","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110870","article-title":"Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids","volume":"39","author":"Li","year":"2022","journal-title":"Cell Rep"},{"issue":"52","key":"10.1016\/j.gendis.2026.102157_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408049121","article-title":"ACSL4-mediated H3K9 and H3K27 hyperacetylation upregulates SNAIL to drive TNBC metastasis","volume":"121","author":"Sinha","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib59","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1084\/jem.20111512","article-title":"MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition","volume":"209","author":"Horiuchi","year":"2012","journal-title":"J Exp Med"},{"issue":"7598","key":"10.1016\/j.gendis.2026.102157_bib60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature17393","article-title":"Reductive carboxylation supports redox homeostasis during anchorage-independent growth","volume":"532","author":"Jiang","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.gendis.2026.102157_bib61","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/biom9110735","article-title":"Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements","volume":"9","author":"Aggarwal","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.gendis.2026.102157_bib62","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fonc.2019.00480","article-title":"Breast cancer subtypes present a differential production of reactive oxygen species (ROS) and susceptibility to antioxidant treatment","volume":"9","author":"Sarmiento-Salinas","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antiox7010013","article-title":"Reactive oxygen species and mitochondrial dynamics: the Yin and Yang of mitochondrial dysfunction and cancer progression","volume":"7","author":"Je\u017eek","year":"2018","journal-title":"Antioxidants"},{"issue":"8","key":"10.1016\/j.gendis.2026.102157_bib64","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-15-1538","article-title":"Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1\u03b1","volume":"76","author":"Lim","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2026.102157_bib65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.redox.2017.12.009","article-title":"Impaired pentose phosphate pathway in the development of 3D MCF-7 cells mediated intracellular redox disturbance and multi-cellular resistance without drug induction","volume":"15","author":"Wang","year":"2018","journal-title":"Redox Biol"},{"issue":"10","key":"10.1016\/j.gendis.2026.102157_bib66","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/bjc.2014.586","article-title":"Redox signalling to nuclear regulatory proteins by reactive oxygen species contributes to oestrogen-induced growth of breast cancer cells","volume":"112","author":"Okoh","year":"2015","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.gendis.2026.102157_bib67","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","article-title":"Mechanisms of ferroptosis","volume":"73","author":"Cao","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib68","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jcp.29062","article-title":"A loop involving NRF2, miR-29b-1-5p and AKT, regulates cell fate of MDA-MB-231 triple-negative breast cancer cells","volume":"235","author":"De Blasio","year":"2020","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib69","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4048\/jbc.2023.26.e42","article-title":"High expression of NRF2 and low expression of KEAP1 predict worse survival in patients with operable triple-negative breast cancer","volume":"26","author":"Lee","year":"2023","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.gendis.2026.102157_bib70","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.freeradbiomed.2021.04.006","article-title":"Nrf2 inhibition sensitizes breast cancer stem cells to ionizing radiation via suppressing DNA repair","volume":"169","author":"Qin","year":"2021","journal-title":"Free Radic Biol Med"},{"issue":"22","key":"10.1016\/j.gendis.2026.102157_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/app112210806","article-title":"Cancer chemopreventive role of dietary terpenoids by modulating Keap1-Nrf2-ARE signaling system: a comprehensive update","volume":"11","author":"Siraj","year":"2021","journal-title":"Appl Sci"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib72","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","article-title":"Regulated cell death (RCD) in cancer: key pathways and targeted therapies","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib73","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43042-024-00485-7","article-title":"Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context","volume":"25","author":"Saddam","year":"2024","journal-title":"Egypt J Med Hum Genet"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib74","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/nu13041212","article-title":"The anticancer effects of flavonoids through miRNAs modulations in triple-negative breast cancer","volume":"13","author":"Adinew","year":"2021","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib75","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.3390\/ijms19123950","article-title":"Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy","volume":"19","author":"Garc\u00eda-Aranda","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib76","first-page":"11","article-title":"Quercetin synergistically enhances the anticancer efficacy of docetaxel through induction of apoptosis and modulation of PI3K\/AKT, MAPK\/ERK, and JAK\/STAT3 signaling pathways in MDA-MB-231 breast cancer cell line","volume":"10","author":"Safi","year":"2021","journal-title":"Int J Mol Cell Med"},{"issue":"1\u20132","key":"10.1016\/j.gendis.2026.102157_bib77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib78","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbcan.2017.06.004","article-title":"BCL2: a promising cancer therapeutic target","volume":"1868","author":"Radha","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"11","key":"10.1016\/j.gendis.2026.102157_bib79","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","article-title":"PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges","volume":"24","author":"Khan","year":"2019","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41419-017-0169-2","article-title":"Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib81","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/cancers14010248","article-title":"Epigenetic priming with decitabine augments the therapeutic effect of cisplatin on triple-negative breast cancer cells through induction of proapoptotic factor NOXA","volume":"14","author":"Nakajima","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.gendis.2026.102157_bib82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fnut.2020.00159","article-title":"Epigenetic regulation and dietary control of triple negative breast cancer","volume":"7","author":"Selmin","year":"2020","journal-title":"Front Nutr"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib83","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"issue":"7283","key":"10.1016\/j.gendis.2026.102157_bib84","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib85","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol"},{"key":"10.1016\/j.gendis.2026.102157_bib86","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-015-0397-y","article-title":"Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer","volume":"14","author":"Zhang","year":"2015","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib87","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/cdd.2015.73","article-title":"Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer","volume":"22","author":"Goodwin","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.gendis.2026.102157_bib88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41419-017-0039-y","article-title":"Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells","volume":"9","author":"Lucantoni","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.gendis.2026.102157_bib89","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8494031","article-title":"Nuclear imaging study of the pharmacodynamic effects of debio 1143, an antagonist of multiple inhibitor of apoptosis proteins (IAPs), in a triple-negative breast cancer model","volume":"2018","author":"Bellaye","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"issue":"45","key":"10.1016\/j.gendis.2026.102157_bib90","doi-asserted-by":"crossref","first-page":"78781","DOI":"10.18632\/oncotarget.20227","article-title":"Cellular inhibitor of apoptosis protein 2 promotes the epithelial-mesenchymal transition in triple-negative breast cancer cells through activation of the AKT signaling pathway","volume":"8","author":"Jo","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib91","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/cells9051118","article-title":"IAP-mediated protein ubiquitination in regulating cell signaling","volume":"9","author":"Dum\u00e9tier","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.gendis.2026.102157_bib92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2014.05.002","article-title":"Targeting apoptosis for anticancer therapy","volume":"31","author":"Fulda","year":"2015","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib93","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.3390\/cells10123465","article-title":"Killing by degradation: regulation of apoptosis by the ubiquitin-proteasome-system","volume":"10","author":"Abbas","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.gendis.2026.102157_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107610","article-title":"The multiple roles of the IAP super-family in cancer","volume":"214","author":"Kumar","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib95","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-012-2352-6","article-title":"Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-\u03b1-independent mechanism","volume":"137","author":"Allensworth","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib96","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Fulda","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib97","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12957-022-02799-5","article-title":"Roles of mitochondrial fusion and fission in breast cancer progression: a systematic review","volume":"20","author":"Xing","year":"2022","journal-title":"World J Surg Oncol"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib98","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s11912-022-01333-w","article-title":"Mitochondrial dynamin-related protein Drp1: a new player in cardio-oncology","volume":"24","author":"Deng","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib99","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.18632\/oncotarget.1944","article-title":"Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells","volume":"5","author":"Qian","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/ars.2019.7898","article-title":"Mitochondrial dysfunction at the center of cancer therapy","volume":"32","author":"Chiu","year":"2020","journal-title":"Antioxid Redox Signal"},{"issue":"29","key":"10.1016\/j.gendis.2026.102157_bib101","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1038\/s41388-021-01869-4","article-title":"Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with doxorubicin displays promising therapeutic efficacy in TNBC","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib102","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41556-022-00843-w","article-title":"Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance","volume":"24","author":"Romani","year":"2022","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib103","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1096\/fj.201901467R","article-title":"Identification of novel dynamin-related protein 1 (Drp1) GTPase inhibitors: therapeutic potential of Drpitor1 and Drpitor1a in cancer and cardiac ischemia-reperfusion injury","volume":"34","author":"Wu","year":"2020","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib104","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.devcel.2007.11.019","article-title":"Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax\/Bak-dependent mitochondrial outer membrane permeabilization","volume":"14","author":"Cassidy-Stone","year":"2008","journal-title":"Dev Cell"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib105","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13730","article-title":"BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple-negative breast cancer (TNBC) cells","volume":"57","author":"Rossi","year":"2024","journal-title":"Cell Prolif"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib106","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/biomedicines10030520","article-title":"Mitochondrial determinants of anti-cancer drug-induced cardiotoxicity","volume":"10","author":"Rocca","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.gendis.2026.102157_bib107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fcell.2018.00113","article-title":"Metabolic targeting of breast cancer cells with the 2-deoxy-D-glucose and the mitochondrial bioenergetics inhibitor MDIVI-1","volume":"6","author":"Lucantoni","year":"2018","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102157_bib108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41419-024-06829-w","article-title":"ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission","volume":"15","author":"Yu","year":"2024","journal-title":"Cell Death Dis"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib109","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1111\/jcmm.13749","article-title":"Dynamin-related protein 1-mediated mitochondrial fission contributes to IR-783-induced apoptosis in human breast cancer cells","volume":"22","author":"Tang","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41401-021-00715-3","article-title":"Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis","volume":"43","author":"Shen","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib111","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1172\/JCI87191","article-title":"Dynamin impacts homology-directed repair and breast cancer response to chemotherapy","volume":"128","author":"Chernikova","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gendis.2026.102157_bib112","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.abb.2019.05.009","article-title":"Silibinin-induced apoptosis of breast cancer cells involves mitochondrial impairment","volume":"671","author":"Si","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.gendis.2026.102157_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108284","article-title":"Silibinin-induced mitochondria fission leads to mitophagy, which attenuates silibinin-induced apoptosis in MCF-7 and MDA-MB-231 cells","volume":"685","author":"Si","year":"2020","journal-title":"Arch Biochem Biophys"},{"issue":"1\u20132","key":"10.1016\/j.gendis.2026.102157_bib114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11010-019-03640-6","article-title":"Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion","volume":"463","author":"Si","year":"2020","journal-title":"Mol Cell Biochem"},{"issue":"14","key":"10.1016\/j.gendis.2026.102157_bib115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41388-023-02596-8","article-title":"Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment","volume":"42","author":"Baek","year":"2023","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13058-020-01301-x","article-title":"Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer","volume":"22","author":"Humphries","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib117","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.chembiol.2017.12.001","article-title":"Identification of new activators of mitochondrial fusion reveals a link between mitochondrial morphology and pyrimidine metabolism","volume":"25","author":"Miret-Casals","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib118","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41420-023-01536-5","article-title":"The ELK3-DRP1 axis determines the chemosensitivity of triple-negative breast cancer cells to CDDP by regulating mitochondrial dynamics","volume":"9","author":"Park","year":"2023","journal-title":"Cell Death Discov"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib119","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12491","article-title":"Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1\u03b1 pathway","volume":"65","author":"Ding","year":"2018","journal-title":"J Pineal Res"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13058-014-0434-6","article-title":"Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential","volume":"16","author":"Pelicano","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib121","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/ijms24032606","article-title":"Modulating glycolysis to improve cancer therapy","volume":"24","author":"Chelakkot","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.gendis.2026.102157_bib122","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3390\/molecules25204831","article-title":"Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy","volume":"25","author":"Li","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib123","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1186\/s12885-020-07414-y","article-title":"Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness","volume":"20","author":"Fujita","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib124","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1038\/s41598-019-39789-9","article-title":"2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype","volume":"9","author":"O\u2019Neill","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.60","article-title":"Targeting cellular metabolism to improve cancer therapeutics","volume":"4","author":"Zhao","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.gendis.2026.102157_bib126","doi-asserted-by":"crossref","first-page":"647","DOI":"10.54097\/fpsca663","article-title":"Targeting metabolic pathways improves TNBC therapy","volume":"74","author":"Yang","year":"2023","journal-title":"Highlights Sci Eng Technol"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib127","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1039\/c4pp00288a","article-title":"Energy metabolism targeted drugs synergize with photodynamic therapy to potentiate breast cancer cell death","volume":"13","author":"Feng","year":"2014","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/j.gendis.2026.102157_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1060495","article-title":"Correlation between the Warburg effect and progression of triple-negative breast cancer","volume":"12","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.gendis.2026.102157_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1199105","article-title":"Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens","volume":"13","author":"Srivastava","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib130","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge","volume":"8","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib131","doi-asserted-by":"crossref","first-page":"252","DOI":"10.15252\/embj.201695204","article-title":"Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype","volume":"36","author":"Semenza","year":"2017","journal-title":"EMBO J"},{"issue":"10","key":"10.1016\/j.gendis.2026.102157_bib132","first-page":"5155","article-title":"Chemoresistance in breast cancer: PI3K\/Akt pathway inhibitors vs the current chemotherapy","volume":"11","author":"Kaboli","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib133","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10555-016-9637-x","article-title":"PI3K\/AKT\/mTOR: role in breast cancer progression, drug resistance, and treatment","volume":"35","author":"Guerrero-Zotano","year":"2016","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib134","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2018.03.002","article-title":"Rewiring of glutamine metabolism is a bioenergetic adaptation of human cells with mitochondrial DNA mutations","volume":"27","author":"Chen","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40170-020-00235-4","article-title":"In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells","volume":"8","author":"Gonsalves","year":"2020","journal-title":"Cancer Metab"},{"key":"10.1016\/j.gendis.2026.102157_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112980","article-title":"Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer","volume":"210","author":"Zhou","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib137","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.3390\/cancers12092624","article-title":"Metabolic signaling cascades prompted by glutaminolysis in cancer","volume":"12","author":"Shah","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.gendis.2026.102157_bib138","article-title":"Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.gendis.2026.102157_bib139","doi-asserted-by":"crossref","first-page":"9342","DOI":"10.1074\/jbc.RA119.008180","article-title":"Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells","volume":"294","author":"Dos Reis","year":"2019","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib140","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12885-020-06885-3","article-title":"Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer","volume":"20","author":"Singleton","year":"2020","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185092","article-title":"Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition","volume":"12","author":"Lampa","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.gendis.2026.102157_bib142","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.gendis.2022.02.009","article-title":"Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)","volume":"9","author":"Hong","year":"2022","journal-title":"Genes Dis"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib143","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Therapeut"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib144","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.gendis.2026.102157_bib145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbrc.2022.04.068","article-title":"Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma","volume":"611","author":"Kawakami","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib146","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140100","article-title":"Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer","volume":"131","author":"Edwards","year":"2021","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib147","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12951-022-01424-7","article-title":"Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer","volume":"20","author":"Tang","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.gendis.2026.102157_bib148","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2018.05.017","article-title":"Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis","volume":"430","author":"Halama","year":"2018","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib149","article-title":"Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies","volume":"4","author":"Nguyen","year":"2023","journal-title":"Future Drug Disc"},{"issue":"7","key":"10.1016\/j.gendis.2026.102157_bib150","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/cancers11070965","article-title":"Targeting cancer stem cells in triple-negative breast cancer","volume":"11","author":"Park","year":"2019","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.gendis.2026.102157_bib151","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1158\/1541-7786.MCR-19-0264","article-title":"A unique morphological phenotype in chemoresistant triple-negative breast cancer reveals metabolic reprogramming and PLIN4 expression as a molecular vulnerability","volume":"17","author":"Sirois","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib152","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cmet.2023.12.003","article-title":"Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer","volume":"36","author":"Zhang","year":"2024","journal-title":"Cell Metab"},{"issue":"41","key":"10.1016\/j.gendis.2026.102157_bib153","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2443","article-title":"Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer","volume":"7","author":"Loo","year":"2021","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib154","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12272-019-01127-y","article-title":"Mitochondria-centric bioenergetic characteristics in cancer stem-like cells","volume":"42","author":"Shin","year":"2019","journal-title":"Arch Pharm Res"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib155","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/0008-5472.CAN-12-3009","article-title":"Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance","volume":"73","author":"Butler","year":"2013","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.gendis.2026.102157_bib156","doi-asserted-by":"crossref","first-page":"12513","DOI":"10.1073\/pnas.93.22.12513","article-title":"A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity","volume":"93","author":"K\u00e9ri","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"10.1016\/j.gendis.2026.102157_bib157","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/onc.2011.137","article-title":"Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2","volume":"30","author":"Chen","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2026.102157_bib158","doi-asserted-by":"crossref","DOI":"10.1177\/1533034617749418","article-title":"Lapatinib inhibits breast cancer cell proliferation by influencing PKM2 expression","volume":"17","author":"Guan","year":"2018","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib159","doi-asserted-by":"crossref","first-page":"8323","DOI":"10.1038\/s41598-018-25524-3","article-title":"Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1\u03b1 inhibition","volume":"8","author":"Ahmad Siddiqui","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.gendis.2026.102157_bib160","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-12-0595","article-title":"PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy","volume":"3","author":"Tan","year":"2013","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib161","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10549-009-0435-9","article-title":"Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo","volume":"120","author":"Sun","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112282","article-title":"Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer","volume":"396","author":"Umar","year":"2020","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib163","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ymgme.2011.04.003","article-title":"Clotrimazole disrupts glycolysis in human breast cancer without affecting non-tumoral tissues","volume":"103","author":"Coelho","year":"2011","journal-title":"Mol Genet Metabol"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030462","article-title":"Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis","volume":"7","author":"Furtado","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib165","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymgme.2004.11.012","article-title":"Clotrimazole decreases human breast cancer cells viability through alterations in cytoskeleton-associated glycolytic enzymes","volume":"84","author":"Meira","year":"2005","journal-title":"Mol Genet Metabol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib166","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bcp.2008.09.020","article-title":"Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity","volume":"77","author":"Spitz","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"28","key":"10.1016\/j.gendis.2026.102157_bib167","doi-asserted-by":"crossref","first-page":"25677","DOI":"10.18632\/oncotarget.4499","article-title":"A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models","volume":"6","author":"Xintaropoulou","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib168","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/metabo15040250","article-title":"Untargeted metabolomics reveals acylcarnitines as major metabolic targets of resveratrol in breast cancer cells","volume":"15","author":"Falcone","year":"2025","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib169","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10863-015-9637-5","article-title":"Effect of 3-bromopyruvate acid on the redox equilibrium in non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells","volume":"48","author":"Kwiatkowska","year":"2016","journal-title":"J Bioenerg Biomembr"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10863-019-09811-w","article-title":"Effect of methyl jasmonate and 3-bromopyruvate combination therapy on mice bearing the 4 T1 breast cancer cell line","volume":"52","author":"Yousefi","year":"2020","journal-title":"J Bioenerg Biomembr"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib171","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-017-0530-4","article-title":"Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2","volume":"36","author":"Li","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.gendis.2026.102157_bib172","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bmc.2013.02.015","article-title":"A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells","volume":"21","author":"Koh","year":"2013","journal-title":"Bioorg Med Chem"},{"issue":"22","key":"10.1016\/j.gendis.2026.102157_bib173","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4161\/cc.26461","article-title":"Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer","volume":"12","author":"Marini","year":"2013","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib174","first-page":"129","article-title":"Metformin targets glucose metabolism in triple negative breast cancer","volume":"4","author":"Wahdan-Alaswad","year":"2018","journal-title":"J Oncol Transl Res"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4161\/cc.11.2.18813","article-title":"Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers","volume":"11","author":"Deng","year":"2012","journal-title":"Cell Cycle"},{"issue":"8","key":"10.1016\/j.gendis.2026.102157_bib176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136250","article-title":"Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions","volume":"10","author":"Silvestri","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.gendis.2026.102157_bib177","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.3390\/cancers12082252","article-title":"Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer","volume":"12","author":"Varghese","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib178","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/nbm.3240","article-title":"Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin","volume":"28","author":"Nath","year":"2015","journal-title":"NMR Biomed"},{"issue":"36","key":"10.1016\/j.gendis.2026.102157_bib179","doi-asserted-by":"crossref","first-page":"32670","DOI":"10.1021\/acsami.9b09886","article-title":"Antitumor effect of lonidamine-polypeptide-peptide nanoparticles in breast cancer models","volume":"11","author":"Cohen-Erez","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12672-017-0285-6","article-title":"MMTV-PyMT and derived met-1 mouse mammary tumor cells as models for studying the role of the androgen receptor in triple-negative breast cancer progression","volume":"8","author":"Christenson","year":"2017","journal-title":"Horm Cancer"},{"issue":"7","key":"10.1016\/j.gendis.2026.102157_bib181","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.gendis.2026.102157_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121775","article-title":"Drug self-delivery nanorods enhance photodynamic therapy of triple-negative breast cancer by inhibiting oxidative phosphorylation","volume":"621","author":"Gao","year":"2022","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib183","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.chembiol.2016.03.017","article-title":"GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity","volume":"23","author":"Louie","year":"2016","journal-title":"Cell Chem Biol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib184","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/bcr2154","article-title":"Targeting aspartate aminotransferase in breast cancer","volume":"10","author":"Thornburg","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.gendis.2026.102157_bib185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1476-4598-9-33","article-title":"Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol","volume":"9","author":"Zhou","year":"2010","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.gendis.2026.102157_bib186","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejps.2012.08.012","article-title":"Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways","volume":"47","author":"Farabegoli","year":"2012","journal-title":"Eur J Pharmaceut Sci"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib187","doi-asserted-by":"crossref","first-page":"297","DOI":"10.33263\/BRIAC133.297","article-title":"Quantitative proteomic assessment of key proteins regulated by electrical pulse-mediated galloflavin delivery in triple-negative breast cancer cells","volume":"13","author":"Giri","year":"2022","journal-title":"Biointerface Res Appl Chem"},{"key":"10.1016\/j.gendis.2026.102157_bib188","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.freeradbiomed.2014.11.003","article-title":"Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2","volume":"78","author":"Olayanju","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.gendis.2026.102157_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2021.152680","article-title":"Apoptotic activities of brusatol in human non-small cell lung cancer cells: involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response","volume":"451","author":"Xie","year":"2021","journal-title":"Toxicology"},{"issue":"9","key":"10.1016\/j.gendis.2026.102157_bib190","doi-asserted-by":"crossref","first-page":"8265","DOI":"10.3390\/ijms24098265","article-title":"Natural compounds, optimal combination of brusatol and polydatin promote anti-tumor effect in breast cancer by targeting Nrf2 signaling pathway","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.gendis.2026.102157_bib191","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/jpp\/rgab018","article-title":"An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells","volume":"73","author":"Chandrasekaran","year":"2021","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib192","first-page":"262","article-title":"Upregulation of NOX-2 and Nrf-2 promotes 5-fluorouracil resistance of human colon carcinoma (HCT-116) cells","volume":"86","author":"Waghela","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.gendis.2026.102157_bib193","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5956867","article-title":"mTOR-mediated antioxidant activation in solid tumor radioresistance","volume":"2019","author":"Woo","year":"2019","journal-title":"J Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2026.102157_bib194","first-page":"6153","article-title":"Differential anticancer activity of pterostilbene against three subtypes of human breast cancer cells","volume":"37","author":"Wakimoto","year":"2017","journal-title":"Anticancer Res"},{"issue":"51","key":"10.1016\/j.gendis.2026.102157_bib195","doi-asserted-by":"crossref","first-page":"11179","DOI":"10.1021\/acs.jafc.7b02358","article-title":"Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells","volume":"65","author":"Hung","year":"2017","journal-title":"J Agric Food Chem"},{"issue":"11","key":"10.1016\/j.gendis.2026.102157_bib196","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141913","article-title":"Monitoring the antioxidant mediated chemosensitization and ARE-signaling in triple negative breast cancer therapy","volume":"10","author":"Foygel","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib197","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/antiox10020169","article-title":"Possible beneficial effects of N-acetylcysteine for treatment of triple-negative breast cancer","volume":"10","author":"Kwon","year":"2021","journal-title":"Antioxidants"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib198","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib199","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/hsz-2018-0233","article-title":"Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations","volume":"400","author":"Henz","year":"2019","journal-title":"Biol Chem"},{"issue":"11","key":"10.1016\/j.gendis.2026.102157_bib200","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.tips.2020.09.004","article-title":"BH3 mimetics in AML therapy: death and beyond?","volume":"41","author":"Cerella","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.gendis.2026.102157_bib201","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3324\/haematol.2018.204701","article-title":"Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies","volume":"104","author":"Al-Zebeeby","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.gendis.2026.102157_bib202","doi-asserted-by":"crossref","DOI":"10.1038\/srep26643","article-title":"MUC1-C stabilizes MCL-1 in the oxidative stress response of triple-negative breast cancer cells to BCL-2 inhibitors","volume":"6","author":"Hiraki","year":"2016","journal-title":"Sci Rep"},{"issue":"39","key":"10.1016\/j.gendis.2026.102157_bib203","doi-asserted-by":"crossref","first-page":"25545","DOI":"10.18632\/oncotarget.25370","article-title":"Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin","volume":"9","author":"Inao","year":"2018","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.gendis.2026.102157_bib204","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1158\/0008-5472.CAN-16-3424","article-title":"Inhibition of mitochondrial matrix chaperones and antiapoptotic Bcl-2 family proteins empower antitumor therapeutic responses","volume":"77","author":"Karpel-Massler","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102157_bib205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3892\/ijo.2021.5292","article-title":"Synergism of a novel MCL-1 downregulator, acriflavine, with navitoclax (ABT-263) in triple-negative breast cancer, lung adenocarcinoma and glioblastoma multiforme","volume":"60","author":"Lee","year":"2022","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib206","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/0008-5472.CAN-16-1901","article-title":"Systematic drug screening identifies tractable targeted combination therapies in triple-negative breast cancer","volume":"77","author":"Wali","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2026.102157_bib207","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.tiv.2016.10.002","article-title":"Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells","volume":"38","author":"Hamunyela","year":"2017","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"10.1016\/j.gendis.2026.102157_bib208","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1158\/1535-7163.MCT-19-1160","article-title":"Birinapant enhances gemcitabine\u2019s antitumor efficacy in triple-negative breast cancer by inducing intrinsic pathway-dependent apoptosis","volume":"20","author":"Xie","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"3","key":"10.1016\/j.gendis.2026.102157_bib209","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1078-0432.CCR-17-3852","article-title":"SMAC mimetic debio 1143 and ablative radiation therapy synergize to enhance antitumor immunity against lung cancer","volume":"25","author":"Tao","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3\u20134","key":"10.1016\/j.gendis.2026.102157_bib210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10911-012-9265-1","article-title":"Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics","volume":"17","author":"Wang","year":"2012","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"8","key":"10.1016\/j.gendis.2026.102157_bib211","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1021\/jm101505d","article-title":"A potent and orally active antagonist (SM-406\/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment","volume":"54","author":"Cai","year":"2011","journal-title":"J Med Chem"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226001297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226001297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:42:15Z","timestamp":1790012535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304226001297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":211,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2352304226001297"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102157","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitochondrial dynamics: A promising tool for personalized TNBC management","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102157"}}